Condition: Resistant Arterial Hypertension · Chronic Kidney Disease (Stage 3-4) · Sponsor: The First Affiliated Hospital with Nanjing Medical University
This is a single-center, open-label, exploratory clinical study designed to evaluate the safety and efficacy of a single-session injection of SC101, a small interfering RNA (siRNA) agent, into the perirenal fat. This study plans to enroll 3 participants, aged 18 to 65 years, who have a clinical diagnosis of resistant hypertension and moderate to severe chronic kidney disease (CKD).
This description comes directly from the study's public registry record.
Xiangqing Kong, MD, PhD · +86 13951610265 · kongxq@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| Suzhou Municipal Hospital | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07483372